Floatz logo

Idarubicine

Conditioning

Nanfang Hospital, Southern Medical UniversityPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Conditioning cohort.

Asset / SponsorPhaseRating
Evomela
First Affiliated Hospital of Zhejiang University
Phase 3BB
Fludarabine
First Affiliated Hospital of Zhejiang University
Phase 3BB
Cyclophosphamide
First Affiliated Hospital Xi'an Jiaotong University
Phase 2/3B
Busulphan
First Affiliated Hospital Xi'an Jiaotong University
Phase 2/3B
FILGRASTIM
First Affiliated Hospital Xi'an Jiaotong University
Phase 2/3B

View all 15 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →